Physician

Arshad Kaleem, MD, DMD

According to 2025 Medicare claims, Arshad Kaleem, MD, DMD (NPI: 1134380959) practices maxillofacial surgery in the El Paso, TX market, with the plurality of this provider's patient population coming from El Paso, TX. This provider's primary affiliated billing organization is UMC EL PASO HEALTHCARE INC (NPI: 1528683810; TIN: 844007624) and primary practice location at 79905-2705.

Kaleem's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 48 traditional Medicare patients, billed 124 HCPCS/CPT codes, and received $26,300 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 160 prescription claims across 59 beneficiaries totaling $2,384 in drug costs, led by Doxycycline Hyclate (Doxycycline Hyclate). Open Payments data shows 16 records totaling $942. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $47,575 to $26,300. Similarly, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $21,099 to $2,384. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$49K$97K2018 Medicare payment: $47,575 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $55,474 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $80,642 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $97,117 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $10,582 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $7,441 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $26,300 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
201853131$47,575
201946136$55,474
202092273$80,642
2021130418$97,117
202248101$10,582
20232748$7,441
202448124$26,300

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$11K$21K2015 Drug cost: $21,099 (USD; Tot_Drug_Cst)2016 Drug cost: $20,744 (USD; Tot_Drug_Cst)2017 Drug cost: $17,368 (USD; Tot_Drug_Cst)2018 Drug cost: $962 (USD; Tot_Drug_Cst)2019 Drug cost: $515 (USD; Tot_Drug_Cst)2020 Drug cost: $3,557 (USD; Tot_Drug_Cst)2021 Drug cost: $8,183 (USD; Tot_Drug_Cst)2022 Drug cost: $5,649 (USD; Tot_Drug_Cst)2023 Drug cost: $1,797 (USD; Tot_Drug_Cst)2024 Drug cost: $2,384 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201556165$21,099
201660219$20,744
201752170$17,368
20181641$962
20191737$515
202036116$3,557
202174243$8,183
202260205$5,649
202345103$1,797
202459160$2,384

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99204New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more1616$117
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more1419$69
99212Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more1631$41

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Doxycycline HyclateDoxycycline Hyclate16739$484
PentoxifyllinePentoxifylline11645$350
Chlorhexidine GluconateChlorhexidine Gluconate601,213$223
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13216$172
IbuprofenIbuprofen16186$103

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.16$942Inspire Medical Systems, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Arshad Kaleem, MD, DMD?

Tedicare shows public-source Medicare data for Arshad Kaleem, MD, DMD (NPI 1134380959), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Arshad Kaleem, MD, DMD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Arshad Kaleem, MD, DMD?

Arshad Kaleem, MD, DMD is linked to UMC EL PASO HEALTHCARE INC (billing NPI 1528683810) in the available physician profile data.

Does Arshad Kaleem, MD, DMD have Open Payments data?

Arshad Kaleem, MD, DMD has 16 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.